iCo Therapeutics Inc., a Vancouver based reprofiling development company, have announced their intention to recruit patients for a Phase II DME clinical trial of their proprietary anti-sense therapeutic. The experimental drug, “iCo-007”, is a second generation anti-sense RNA molecule designed to target c-Raf kinase mRNA, believed to represent a key upstream target in angiogenesis. In a company press release Dr. Peter Hnik, Chief Medical Officer of iCo Therapeutics stated that “our phase I clinical study indicated encouraging results in patients refractory to other treatment options and now we will be able study drug safety and efficacy in a broader patient population”.